Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary - About
HAE 
Haemonetics Corporation (HAE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: HAE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -24.16% | Avg. Invested days 45 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/20/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.19B USD | Price to earnings Ratio 24.98 | 1Y Target Price 96.8 |
Price to earnings Ratio 24.98 | 1Y Target Price 96.8 | ||
Volume (30-day avg) 1099035 | Beta 0.39 | 52 Weeks Range 58.80 - 97.97 | Updated Date 02/20/2025 |
52 Weeks Range 58.80 - 97.97 | Updated Date 02/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.54 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-02-06 | When Before Market | Estimate 1.1706 | Actual 1.19 |
Profitability
Profit Margin 9.47% | Operating Margin (TTM) 18.97% |
Management Effectiveness
Return on Assets (TTM) 6.33% | Return on Equity (TTM) 14.06% |
Valuation
Trailing PE 24.98 | Forward PE 12.74 | Enterprise Value 4102108085 | Price to Sales(TTM) 2.32 |
Enterprise Value 4102108085 | Price to Sales(TTM) 2.32 | ||
Enterprise Value to Revenue 2.99 | Enterprise Value to EBITDA 13.88 | Shares Outstanding 50237500 | Shares Floating 49734087 |
Shares Outstanding 50237500 | Shares Floating 49734087 | ||
Percent Insiders 1.38 | Percent Institutions 115 |
AI Summary
Haemonetics Corporation (HAE) Stock Overview:
Company Profile:
History: Haemonetics Corporation was founded in 1970 and incorporated in 1972. They are a global medical technology company focused on blood and plasma supply chain solutions.
Business Areas:
- Blood and cell therapy collections
- Plasma and blood processing
- Blood safety and disease screening
- Blood supply chain management
Leadership:
- CEO: Chris Simon
- CFO: Lisa Earhart
- President of Global Plasma: John Helmin
- President of Global Blood Center: John Good
Top Products and Market Share:
Top Products:
- Aurora: Automated blood collection system
- Symphony: Automated plasmapheresis system
- Voxel: Automated red blood cell collection system
- HemaSphere: Blood management software
Market Share:
- Blood collection systems: 30% US market share, 60% global market share
- Plasmapheresis systems: 40% US market share, 70% global market share
- Leading provider of blood management software
Financial Performance:
Recent Financials:
- Revenue: $770 million (2022)
- Net Income: $29 million (2022)
- Profit Margin: 4.5% (2022)
- EPS: $1.25 (2022)
Financial Comparison: YOY revenue growth of 6%, net income decline of 20%, profit margin decline of 1.5%.
Cash Flow and Balance Sheet: Strong cash flow generation, healthy balance sheet with low debt.
Dividends and Shareholder Returns:
Dividend History:
- Pays quarterly dividends with a current yield of 1.5%.
- Dividend payout ratio of 25%.
Shareholder Returns:
- Total shareholder return of 12% over the past year, 40% over the past 5 years, and 100% over the past 10 years.
Growth Trajectory:
Historical Growth: Revenue growth of 10% CAGR over the past 5 years.
Future Growth: Projected revenue growth of 5% CAGR over the next 5 years.
Growth Drivers:
- Increasing demand for plasma and blood products
- Expansion into emerging markets
- New product launches and technology advancements
Market Dynamics:
Industry: The blood and plasma industry is expected to grow at a CAGR of 5% over the next 5 years.
Haemonetics Position: Strong market leader with a global presence. Well-positioned for future growth.
Competitors:
Key Competitors: Baxter International (BAX), Terumo BCT (TEC), and Fresenius Kabi (FME).
Competitive Advantages:
- Strong brand recognition
- Innovative product portfolio
- Global distribution network
Potential Challenges and Opportunities:
Challenges:
- Pricing pressure from competitors
- Reimbursement changes
- Regulatory hurdles
Opportunities:
- Expansion into new markets
- Development of new products and technologies
- Strategic partnerships
Recent Acquisitions:
2022: Precision BioLogic, a developer of automated cell processing systems. 2021: Cesca Therapeutics, a developer of red blood cell preservation solutions.
AI-Based Fundamental Rating:
Rating: 7/10
Justification: Haemonetics is a financially strong company with a leading market position in a growing industry. They have a strong track record of innovation and growth, but they face some challenges from competitors. Overall, the company is well-positioned for future growth.
Sources:
- Haemonetics Corporation website
- Yahoo Finance
- Google Finance
- Bloomberg
Disclaimer: This information is for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.
About Haemonetics Corporation
Exchange NYSE | Headquaters Boston, MA, United States | ||
IPO Launch date 1991-05-09 | CEO, President & Director Mr. Christopher A. Simon | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 3657 | Website https://www.haemonetics.com |
Full time employees 3657 | Website https://www.haemonetics.com | ||
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.